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Cardiac glycosides, known ligands of the sodium pump, are widely used in the treatment of heart failure,
such as digoxin and digitoxin. Besides this important activity, other biological activities, such as the anti-
viral activity, have been described for this group. HSV are responsible for many infections of oral, ocular
and genital regions. Treatment with nucleoside analogs such as acyclovir is effective in most cases;
however drug-resistance may arise due to prolonged treatment mainly in immunocompromised individ-
uals. In this study, an antiherpes screening was performed with 65 cardenolide derivatives obtained from
different sources, and one natural cardenolide, glucoevatromonoside, inhibited HSV-1 and HSV-2 replica-
tion at very low concentrations. This cardenolide showed viral inhibitory effects if added up to 12 h p.i.
and these effects appear to take place by the inhibition of viral proteins synthesis (ICP27, UL42, gB, gD),
the blockage of virus release and the reduction of viral cell-to-cell spread. This compound also showed
synergistic antiviral effects with acyclovir and anti-Na+K+ATPase activity, suggesting that cellular electro-
chemical gradient alterations might be involved in the mechanism of viral inhibition. These results sug-
gest that cardenolides might be promising for future antiviral drug design.
 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Herpes Simplex Virus types 1 and 2 (HSV-1; HSV-2) are alpha-
herpesviruses with double-stranded DNA packed in an icosahedral
capsid and a lipidic envelope formed by various glycoproteins.
They replicate by three rounds of transcription, resulting in a
(immediate early) proteins that mainly regulate viral replication,
such as ICP27; b (early) proteins that synthesize and package
DNA, such as UL42; and c (late) proteins, most of which are virion
proteins, like gB and gD. Inhibition of any of the former stages
blocks HSV replication and therefore are potential targets for anti-
viral therapy (Roizman et al., 2007). The vast majority of the cur-
rently licensed drugs for the systemic and/or topical treatment of
herpesvirus infections share the same target, the viral DNA poly-
merase, and the nucleoside analogs are the most widely used drugsharmaceutical Sciences, CCS,
dade, 88.040-900 Florianóp-
21 9258.
imões).
evier OA license.for the treatment of such infections (De Clercq, 2009). The develop-
ment of new antiviral molecules derived from acyclovir increases
the selection pressure risk of resistant strains (Danve-Szatanek
et al., 2004) that have been observed in vivo since the ﬁrst large
therapeutic trials (McLaren et al., 1985). Therefore, the search for
new antiviral agents, especially those with different mechanisms
of action, is a crucial goal (Butler, 2008).
Cardiac glycosides belong to a group of naturally derived com-
pounds that bind to and inhibit Na+K+ATPase (Lingrel et al., 1997).
Members of this group have been traditionally used for the treat-
ment of heart failure and atrial arrhythmia, such as digoxin, digi-
toxin and ouabain (Rahimtoola and Tak, 1996). Recently, other
important applications have been suggested for these compounds
related to their potential anticancer (Prassas and Diamandis,
2008) and antiviral activity (Dodson et al., 2007; Hartley et al.,
2006; Hoffmann et al., 2008; Su et al., 2008).
In this report, we screened 65 cardenolide derivatives obtained
from plants, by synthesis or by fungi biotransformation, for anti
HSV-1 and HSV-2 activity. Among them, glucoevatromonoside
(Fig. 1), isolated from a Brazilian cultivar of Digitalis lanata (Braga
et al., 1996) was chosen for its lower IC50 against HSV to further
elucidate its mechanism of action.
Fig. 1. Chemical structure of glucoevatromonoside (GEV).
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2.1. Compounds, cells and viruses
The 65 tested cardenolide derivatives were obtained from plants
(Braga et al., 1996; Braga et al., 1997), by synthesis (Extrasynthèse,
Genay, France; Merck, Darmstadt, Germany; Boehringer, Mann-
heim, Germany; Carl Roth, Karlsruhe, Germany), or by fungi
biotransformation (Pádua et al., 2005; Pádua et al., 2007). Acyclovir,
digoxin, dextran sulfate and furosemide were obtained from Sigma
(St. Louis,MO,USA). All compoundswere dissolved in dimethyl sulf-
oxide (DMSO) (Merck, Darmstadt, Germany), not exceeding the
minimumnoncytotoxic concentration of 1%DMSOandwere further
diluted in culture medium prior its use.
Vero (ATCC:CCL81) andGMK-AH1(Departmentof ClinicalVirol-
ogy, University of Göteborg, Sweden) cells were grown in Eagle’s
minimum essential medium (MEM; Cultilab, Campinas, Brazil)
supplemented with 10% fetal bovine serum (FBS; Gibco, Carlsbad,
CA), 100 U/mL penicillin G, 100 lg/mL streptomycin and 25 lg/mL
amphotericin B (Cultilab) and maintained at 37 C in a humidiﬁed
5% CO2.
HSV-1 [KOS and 29R (acyclovir-resistant) strains] (Faculty of
Pharmacy, University of Rennes, France), and HSV-2 [333 strain
(Department of Clinical Virology, Göteborg University, Sweden)]
were propagated in Vero and GMK AH1 cells, respectively. Viral
stocks were stored at 80C and titrated based on plaque forming
units (PFU) count by plaque assay as previously described (Burle-
son et al., 1992).2.2. Screening for antiherpes compounds
Firstly, cytotoxicity was determined by MTT assay (Mosmann,
1983). Brieﬂy, conﬂuent Vero or GMK cells were exposed to differ-
ent concentrations of compounds for 72 or 48 h, respectively, and
after incubation, the 50% cytotoxic concentration (CC50) of each
one was calculated as the concentration that reduces cell viability
by 50%, when compared to the untreated control.
After that, to screen antiherpes activity, a plaque reduction assay
was performed following the general procedures described by Silva
et al. (2010). Cell monolayers were infected with approximately
100 PFU of each virus for 1 h at 37 C and then were overlaid with
MEM containing 1.5% carboxymethylcellulose (CMC; Sigma) either
with the presence or absence of different concentrations of the
compounds. After 48 h (HSV-2) or 72 h (HSV-1) of incubation at
37 C, cells were ﬁxed and stained with naphthol blue–black
(Sigma), and plaques were counted. The IC50 of each compound
was calculated as the concentration that inhibited 50% of viral pla-
que formation, when compared to untreated controls. Acyclovir
was used as positive control. The selectivity index (SI = CC50/IC50)
was calculated for each tested compound.2.3. Assays for anti-HSV-1 (KOS strain) activity
To investigate the potency of the detected antiherpes activity,
an yield reduction assay was performed as previously described
by Hussein et al. (2008). Vero cell monolayers were infected with
HSV-1 at three different MOI (0.004, 0.04 and 0.4) for 1 h at
37 C. Cells were washed, different concentrations of glucoevatro-
monoside were added, and the plates incubated during 72 h at
37 C. After, culture supernatants were harvested and virus titers
were calculated by plaque reduction assay as previously described.
The virucidal assay was conducted as described by Ekblad et al.
(2006), where the mixtures of serial two-fold dilutions of glucoev-
atromonoside and 4  104 PFU of HSV-1 in serum free MEM were
co-incubated for 15 min at 37 C prior to the dilution of these mix-
tures to non-inhibitory concentrations of this compound (1:100).
The residual infectivity was determined by viral plaque reduction
assay as described above.
The pretreatment (Bettega et al., 2004) was performed with
Vero cell monolayers, which were pretreated with different con-
centrations of glucoevatromonoside for 3 h at 37 C prior virus
infection. After washing, cells were infected with 100 PFU of
HSV-1 for 1 h at 37 C. The infected cells were washed, overlaid
with MEM containing 1.5% CMC, incubated for 72 h, and treated
as described earlier for plaque reduction assay. For the simulta-
neous treatment (Onozato et al., 2009), 100 PFU of HSV-1 and dif-
ferent concentrations of glucoevatromonoside were added
concomitantly to Vero cells for 1 h at 37 C. After washing, cells
were overlaid with MEM containing 1.5% CMC, incubated for
72 h, and treated as described earlier for plaque reduction assay.
The attachment and penetration assays followed the procedures
also described by Silva et al. (2010). Brieﬂy, for attachment assay,
conﬂuent Vero cells prechilled at 4 C for 1 h were infected with
100 PFU of HSV-1, treated with different concentrations of glu-
coevatromonoside, and incubated at 4 C for 2 h. Unabsorbed
viruses were removed by washing with cold PBS, and cells were
covered with overlay medium, and treated as formerly described
for plaque reduction assay. For penetration assay, 100 PFU of
HSV-1 were adsorbed for 2 h at 4 C on conﬂuent Vero cells pre-
chilled at 4 C for 1 h, and after incubated at 37 C for 5 min to al-
low virus penetration. Following, cells were treated with different
concentrations of glucoevatromonoside, and incubated for 1 h at
37 C. Unpenetrated viruses were inactivated with warm citrate-
buffer (pH 3.0) for 1 min. Cells were washed with PBS, and treated
as described above for plaque reduction assay. For attachment and
penetration assays, the dextran sulfate (Sigma) was used as a posi-
tive control (Aguilar et al., 2007).
The time-of-addition and removal assays were performed as
previously described by Su et al. (2008) and Zhen et al. (2006), with
minor modiﬁcations. For the time-of-addition assays, Vero cell
monolayers were infected with 100 PFU of HSV-1 and incubated
at 37 C for 1 h. Different concentrations of glucoevatromonoside
were added to the cells at intervals of 3, 6, 9, 12, 18 and 24 h
post-infection (p.i.). After 72 h of incubation, this assay followed
the procedures described earlier for plaque reduction assay. In
the assessment of time-of-removal assays, cells were infected
100 PFU of HSV-1 and incubated at 37 C for 1 h, and different con-
centrations of glucoevatromonoside were added. At the intervals of
3, 6, 9, 12, 18 and 24 h p.i., the medium containing the glucoevatro-
monoside was removed, cells were washed with PBS and only
MEM was added into the wells. After 72 h of incubation, this assay
followed the procedures described earlier for plaque reduction
assay.
For the viral plaque size reduction assay, different concentra-
tions of glucoevatromonoside were added to Vero cells 1 h after
their infection with 100 PFU of HSV-1, and the plates were incu-
bated during the entire period of plaques development. Images of
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of each concentration of glucoevatromonoside were captured using
a cooled digital camera attached to an Olympus BX41 microscope
(Olympus America Inc., Pennsylvania, PA). The area of each plaque
was determined by using the Image J 1.43u version software (NIH,
Bethesda, MD) (Silva et al., 2010).
The virus release assay followed the procedures described by Su
et al. (2008), with minor modiﬁcations. Conﬂuent Vero cells were
infected with HSV-1, at MOI 0.4 for 1 h. After, cell monolayers were
washed and different concentrations of glucoevatromonoside were
added to the cells for 24 h at 37 C. After, the supernatants and cell
pellets were collected separately, and the pellets were frozen and
thawed three times before virus titration by plaque reduction
assay.
2.4. Polymerase chain reaction (PCR)
Genomic DNA and total RNA of Vero cells infected with HSV-1
were extracted using Brazol (LGC Biotecnologia, Cotia, SP, Brazil),
following the manufacture’s instructions. DNase treatment was
performed on the eluted RNA to avoid residual DNA contamina-
tion. Eight hundred nanograms of the eluted RNA was subjected
to reverse transcription by a commercial kit (Superscript™ III;
Invitrogen, Carlsbad, CA, USA), following the manufacture’s
instructions, and then subjected to PCR ampliﬁcation using the
primers pairs for UL54 and UL13 as described Kleymann et al.
(2002) and Tal-Singer et al. (1997) and for UL52 and ACTB (b-actin)
as described by Su et al. (2008). The PCR reaction was carried out in
a ﬁnal volume of 25 ll containing 20 mM Tris–HCl (pH 8.5), 50 mM
KCl, 1.5 mM MgCl2, 0.2 mM of each deoxynucleoside triphosphate,
0.2 lM of each speciﬁc primer, 2.5 U of GoTaq DNA polymerase
(Promega, Madison, WI, USA), and genomic DNA or cDNA. The
PCR program for UL52, UL13 and UL54 and ACTB consists of dena-
turation at 94 C for 5 min and 30 cycles of denaturation at 94 C
for 40 s, annealing at 55 C for 40 s, and polymerization at 72 C
for 40 s, followed by a ﬁnal extension at 72 C for 10 min. The ex-
pected sizes for UL54, UL13, UL52 and ACTB are 283, 600, 259 and
314 bp, respectively. Five-microliter aliquots of the PCR products
were resolved on a 1.5% agarose gel.
2.5. Western blotting analysis
Vero cell monolayers were infected with HSV-1 at MOI 0.2 for
1 h. Next, residual viruses were removed with PBS and cells re-
ceived different treatments for 18 h. Then, cells were trypsinized
and lysed with lysis buffer [0.125 M Tris–HCl (pH 7.4), 30% glyc-
erol, 100 lg/ml phenylmethylsulfonyl ﬂuoride, 2% sodium dodecyl
sulfate and 5% b-mercaptoethanol]. Cell lysates were clariﬁed by
centrifugation, and proteins were denatured by boiling, and equiv-
alent amounts of protein (5 lg) were separated on 12% SDS–poly-
acrylamide gel electrophoresis (SDS–PAGE). The proteins were
transferred to polyvinylidene diﬂuoride (PVDF) membranes
(Millipore, Billerica, MA, USA) and blocked with 5% non-fat milk
in blotting buffer [25 mM Tris–HCl (pH 7.4), 150 mM NaCl, 0.1%
Tween 20]. All membrane washing steps were performed using
this blotting buffer. The membranes were incubated for 90 min
with the following primary antibodies: goat monoclonal antibody
against ICP27 protein (1:700 dilution) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA); mouse monoclonal antibody against UL42
protein (1:5000 dilution) (Millipore); mouse monoclonal antibody
against gD (1:5000 dilution) (Santa Cruz Biotechnology), mouse
monoclonal antibody against gB (1:5000 dilution) (Millipore); rab-
bit monoclonal antibody against b-actin (1:5000 dilution)
(Millipore). After washing, the membranes were incubated with
the respective secondary antibodies for 1 h. The immunoblots were
developed and detected using the Pierce ECL Western BlottingSubstrate (Thermo Scientiﬁc, Rockford, IL, USA), according to the
manufacture’s instructions.
2.6. Evaluation of potential synergistic effects of glucoevatromonoside
plus acyclovir
Potential synergistic effects of glucoevatromonoside with acy-
clovir were evaluated by plaque reduction assay, as described by
Chou (2006). Therefore, each drug by itself or in combination
was tested at an equipotency ratio based on its corresponding
IC50 value. The interaction degree between glucoevatromonoside
and acyclovir was calculated through combination index (CI) equa-
tion, based on the median-effect principle of the mass-action law,
using Calcusyn software (version 2.1, Biosoft). According to the CI
theorem, CI values <1, =1, and >1 indicate synergism, additive ef-
fect, and antagonism, respectively.
2.7. Anti-ATPase assay
This assay followed the procedures described earlier (Hu et al.,
2009). Adenosine 50-triphosphatase (NKATPase) activity assay was
determined using a Quantichrom ATPase/GTPase assay kit (Bioas-
say, Hayward, CA, USA), according to the manufacture’s
instructions.
3. Results and discussion
3.1. Screening for antiherpes compounds
The initial screening of 65 cardenolide derivatives for anti-HSV
activity was performed only with HSV-1(KOS strain) using a plaque
reduction assay. Following the same strategy proposed by Su et al.
(2008), we decided that compounds showing IC50 values 61 lM
would be chosen to proceed another screening for anti-HSV-1
(29R strain) and anti-HSV-2 (333 strain) activity. Among the 65
tested compounds, 16 were found to possess antiherpes activity
with IC50 values 61 lM, and a natural compound, glucoevatro-
monoside, isolated from a Brazilian cultivar of Digitalis lanata
(Braga et al., 1996) was chosen for further evaluation of its mode
of action (Table 1) due to its high SI and lower IC50, when compared
to acyclovir, and also because there was enough quantity to per-
form all designed assays necessary for this purpose. Digoxigenin
showed an IC50 P1 lM, but it was tested in the second screening
because it is the aglycone of some tested cardenolide derivatives
and showed antiherpes effects in a previous work (Su et al.,
2008). As shown in Table 1, HSV-1 (29R strain, resistant to acyclo-
vir) was highly sensitive to the treatment with the tested cardeno-
lides, which implicates that the targets of these compounds are
probably different from those of acyclovir. Hence, they might rep-
resent a novel group of drugs with distinct antiviral mechanism
from those of conventional drugs.
3.2. Mechanism of antiherpes activity of glucoevatromonoside
Firstly, in order to compare the potency of glucoevatromonoside
antiherpes activity, at different MOI, a yield reduction assay was
conducted. As shown in Fig. 2, both concentrations of glucoevatro-
monoside were able to inhibit HSV-1 replication at all tested con-
ditions, even at the MOI 0.4 which is thousand times higher than
that used in the initial screening. At the higher tested MOI, the glu-
coevatromonoside at 0.26 lM, which is two times higher than its
IC50 value, showed a reduction of 5.1 Log, in comparison with viral
controls. Remarkably, this reduction was higher than that obtained
with acyclovir (2.5 Log) at the same conditions Since this antiviral
potency is not commonly observed for other antiviral agents, this
Table 1
Anti-HSV activity of cardenolide derivatives.
Compound (origin) CC50 (lM) HSV-1 (KOS strain) HSV-1 (29R strain) HSV-2 (333 strain)
VERO cells GMK AH1 cells IC50 (lM) SI IC50 (lM) SI IC50 (lM) SI
Digitoxigenin monodigitoxoside (P) 6.60 ± 0.28 >250 0.14 ± 0.00 47 0.11 ± 0.01 60 0.03 ± 0.00 >8.333
Digitoxigenin bisdigitoxoside (P) 10.05 ± 2.33 >250 0.12 ± 0.01 84 0.10 ± 0.01 100 0.09 ± 0.01 >2.777
Glucoevatromonoside (P) 273.95 ± 46.46 >250 0.13 ± 0.01 2.107 0.06 ± 0.01 4.566 0.04 ± 0.00 >6.250
Digitoxin (P) 5.67 ± 0.22 >25 0.34 ± 0.06 17 0.32 ± 002 18 0.20 ± 0.02 >125
b-acetyldigitoxin (P) 10.55 ± 0.49 >250 0.36 ± 0.01 29 0.34 ± 0.01 31 0.50 ± 0.01 >500
Lanatoside A (P) 19.00 ± 0.28 >250 0.54 ± 0.00 35 0.39 ± 0.04 49 0.24 ± 0.00 >1.042
Glucogitoroside (P) 148.50 ± 6.79 >250 0.83 ± 0.01 179 0.60 ± 0.01 247 0.45 ± 0.02 >555
Digoxigenin bisdigitoxoside (P) 174.25 ± 24.68 284.65 ± 16.62 0.27 ± 0.01 645 0.22 ± 0.01 792 0.23 ± 0.02 1.238
Deacetyl lanatoside C (P) 22.15 ± 0.21 >250 0.94 ± 0.05 23 0.44 ± 0.03 50 0.54 ± 0.00 >463
Digoxigenin (P) >250 >250 3.50 ± 0.49 >71 3.56 ± 0.79 >70 1.22 ± 0.01 >205
Digoxin (S) 5.57 ± 0.40 >25 0.66 ± 0.01 8 0.18 ± 0.01 31 0.65 ± 0.01 >38
K strophantoside (S) >250 >250 0.33 ± 0.03 >757 0.50 ± 0.03 >500 0.34 ± 0.04 >735
a-methyldigitoxin (S) 88.50 ± 10.69 >250 0.12 ± 0.20 737 0.25 ± 0.05 354 0.05 ± 0.02 >5.000
b-methyldigitoxin (S) 132.30 ± 8.14 >250 0.14 ± 0.02 945 0.26 ± 0.01 509 0.09 ± 0.01 >2.777
Convalatoxin (S) 201.90 ± 11.46 >250 0.02 ± 0.00 10.095 0.03 ± 0.00 6.730 0.02 ± 0.00 >12.500
Helveticoside (S) >250 >250 0.08 ± 0.00 >3.125 0.11 ± 0.01 >2.273 0.04 ± 0.00 >6.250
Cymarin (S) >250 >250 0.14 ± 0.02 >1.786 0.13 ± 0.01 >1.923 0.11 ± 0.01 >2.273
ACV >2.000 >2.000 3.45 ± 0.42 >580 NA NA 8.60 ± 1.96 >232
Values represent the mean ± standard deviations of three or more independent experiments; CC50 = concentration that showed 50% cytotoxic effects in VERO or GMK AH1
cells; IC50 = concentration that inhibited 50% of HSV replication; IS = CC50/IC50; P = plant origin; S = synthetic origin; NA = no activity.
Fig. 2. Anti-HSV-1 (KOS strain) activity of glucoevatromonoside (GEV, 0.13 and
0.26 lM) at three different MOI values. Acyclovir (ACV, 7 lM) was used as control.
Results represent the mean ± standard deviation of three independent experiments.
() Indicate signiﬁcant statistical differences (p < 0.05), ANOVA/Dunnett tests were
carried out for each treatment in different MOI and compared to their respective
virus controls (VC).
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monte, 2007).
A strategy for the treatment of HSV infections is the topical
application of drugs that can permanently inactivate the viral par-
ticles (Ekblad et al., 2010). To elucidate if glucoevatromonoside
presented virus-inactivating activity, a virucidal assay was per-
formed, where infectious particles of HSV-1 were put in contact
with different concentrations of glucoevatromonoside prior to be
titrated by a plaque reduction assay. This treatment was not able
to inhibit HSV-1 replication, even at a concentration 80 times high-
er (10 lM) than its IC50 (0.13 lM). Therefore, the anti-HSV activity
of this compound was not exerted directly on HSV-1 particles be-
fore they have entered into the cells conﬁrming the ﬁndings previ-
ously described for other cardenolides (Hartley et al., 2006; Nagai
et al., 1972; Su et al., 2008).
To explore the effects of glucoevatromonoside directly on the
host cells, a pretreatment assay was performed. This strategy hasnot shown to inhibit HSV-1 replication, suggesting that this com-
pound did not present prophylactic effect in vitro. Next, HSV-1
and glucoevatromonoside were added to Vero cells simultaneously
to investigate if it could interfere with the early stages of viral
infection. This strategy has also not shown inhibit HSV replication
suggesting that viral adsorption and penetration were not affected.
To conﬁrm these ﬁndings, viral attachment and penetration were
individually investigated, and the results attested that glucoev-
atromonoside indeed did not affect these early stages, even when
tested at 2 lM – 16 times higher than its IC50 (0.13 lM) – corrob-
orating our results obtained during the simultaneous treatment
and those by other authors (Dodson et al., 2007; Su et al., 2008).
Fig. 3 shows a summary of these results.
In order to detect in which stages of HSV replication cycle the
glucoevatromonoside could be acting, time-of-addition and re-
moval assays were performed. As shown in Fig. 4, the anti-HSV-1
activity of glucoevatromonoside was preserved when added up
to 12 h p.i. decreasing thereafter. Concordantly, when glucoevatro-
monoside was removed the activity signiﬁcantly reduced up to12 h
p.i. These data suggested that glucoevatromonoside should be
added up to 12 h p.i. to affect the HSV replication.
Since glucoevatromonoside inhibited HSV-1 at the ﬁrst 12 h of
its replication cycle, after viral attachment and penetration into
the cells, the viral transcription was investigated through RT-PCR
to determine if this process was impaired by this cardenolide
affecting or not the HSV-1 gene expression. For the post-infection
treatment, Vero cells were infected for 1 h, and then treated with
glucoevatromonoside, acyclovir or a combination of both, during
6 and 12 h p.i. Fig. 5 shows the mRNA levels of UL54, UL52 and
UL13 HSV genes, which are a, b and c genes, respectively. The
treatments with glucoevatromonoside (0.13 lM), acyclovir
(5 lM) or a combination of both during 12 h p.i. were not able to
reduce the mRNA expression of the tested genes, when compared
to viral control, indicating that glucoevatromonoside and acyclovir
do not inhibit the transcription process. The same results were ob-
tained when the treatments were performed at 6 h p.i. (data not
shown). Nevertheless, Su et al. (2008) demonstrated that UL52
(b) and UL13 (c) mRNA levels were inhibited by digitoxin. The b-ac-
tin (Fig. 5D), was used as an internal standard, and the expression
level of its mRNA was not affected.
Since the glucoevatromonoside did not inhibit mRNA expres-
sion, the next step of HSV replication to be evaluated was the pro-
Fig. 3. Effects of glucoevatromonoside (GEV) at different stages of HSV-1 (KOS strain) infection by plaque reduction assay. Dextran sulfate (DEX) was used as a positive
control to the attachment and penetration assays. The values represent the mean ± standard deviation of three independent experiments.
Fig. 4. Effects of delayed addition and early removal of glucoevatromonoside (GEV)
on HSV-1 (KOS strain, MOI 0.0004) replication determined by plaque reduction
assay. Results are plotted as% of viral inhibition in comparison to the untreated
controls. The values represent the mean ± standard deviation of three independent
experiments. () Indicate signiﬁcant statistical differences between the tested
sample and virus control (p < 0.01). ANOVA/Dunnett tests were carried out as
appropriate.
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mide + potassium chloride (KCl) as well as their combinations
were also tested. The relevance of intracellular K+ to the viral rep-
lication has already been reported (Hartley et al., 2006; Hartley
et al., 1993; Nagai et al., 1972). Furosemide is a loop diuretic also
known as an inhibitor of Na+K+Cl cotransport activity (NKCC),
which prevents the entry of K+ into the cells (Russel, 2000), and
has also shown antiherpes activity (Hartley et al., 2006). Thus,
furosemide was investigated in order to check if it was able to re-
duce the viral protein levels. Likewise, the supplementation of K+
by adding KCl to the culture medium was also tested to conﬁrm
if this ion was important for the viral inhibition caused by glucoev-
atromonoside. Fig. 6 shows the effects of these treatments on some
HSV-1 proteins and on b-actin that is use as an internal standard.
As shown in Fig. 6, b-actin cell protein was expressed in all treat-
ments; consequently, the tested drugs were not cytotoxic.
The individual treatments with glucoevatromonoside (lane 5)
and acyclovir (lane 3) reduced the levels of all tested viral proteins,
when compared to virus control. The glucoevatromonoside com-
pletely inhibited all viral protein synthesis, whereas acyclovir
was able to inhibit completely only the UL42 and the gB proteins
expression. The treatment with furosemide (lane 8) did not reducethe levels of any viral protein, when compared to viral control indi-
cating that this drug could not affect this stage of HSV-1 replication
or that the tested concentration was insufﬁcient to induce protein
synthesis inhibition.
When the treatment was performed with glucoevatromono-
side + acyclovir (lane 4) or glucoevatromonoside + furosemide
(lane 9), a complete inhibition of protein levels was also detected,
as well as when glucoevatromonoside (lane 5) was tested alone.
Therefore, it was not possible to verify synergistic effects between
glucoevatromonoside and acyclovir or glucoevatromonoside and
furosemide.
However, the inhibition caused by glucoevatromonoside on
HSV protein levels could indicate that the Na+K+ATPase has been
inhibited for this compound, as it is a cardenolide and its inhibition
ability is well established. This inhibition could reduce the K+ con-
centration, and the HSV replication will not occur as usual. Thus,
ability of the glucoevatromonoside to inhibit Na+K+ATPase activity
was also investigated to conﬁrm these data, as demonstrated by
the results below.
If the glucoevatromonoside inhibit the Na+K+ATPase, a reversion
of the viral inhibition by cells exposure to culture medium contain-
ing an increased amount of K+ would be expected. Therefore, MEM
was modiﬁed to contain 27 mM of potassium (5 times more than
in the usual MEM = 5.4 mM). When Vero cells were infected and
remained in this modiﬁed MEM (lane 6), the HSV replication oc-
curred characteristically suggesting that the K+ supplementation
did not cause any alterations to the host cells, and consequently
to the virus replication. In the same way, when the infected cells
were treated with glucoevatromonoside and remained in the mod-
iﬁed medium (lane 7), the viral protein levels were not inhibited.
Furthermore, the treatment with glucoevatromonoside at
0.26 lM (IC100) using the plaque reduction assay performed with
K+ supplementation reestablished 22% of the viral replication
capacity (data not shown), so these results indicated that the ion
K+ is required to HSV-1 replication conﬁrming the results obtained
by Nagai et al. (1972).
Still striving to elucidate the mechanism of antiherpes activity
of glucoevatromonoside, its ability to interfere on virus release
was investigated through the determination of intracellular and
extracellular HSV-1 titers. Digitoxin, an inhibitor of this stage (Su
et al., 2008), was used as a positive control. Every glucoevatro-
monoside tested concentrations signiﬁcantly (p < 0.0001) reduced
the extracellular and intracellular virus titers conﬁrming the inhi-
bition of this step of virus replication (data not shown). For exam-
ple, the lower tested concentration (0.065 lM) reduced the
extracellular and intracellular virus titers more than 99.99% (a
reduction of 4.8 Log) and 90% (a reduction of 1.6 Log), respectively.
Fig. 5. Effects of post-infection treatment (12 h) with glucoevatromonoside (GEV), acyclovir (ACV), and a combination of both on HSV-1 (KOS strain) expression of the
following genes: UL54 (283 pb) (A), UL52 (259 pb) (B), UL13(600 pb) (C) and b-actin (315 pb) (D) by RT-PCR. Columns: 1- treatment with GEV (0.13 lM) plus ACV (5 lM);
2- Virus control (no treatment); 3- treatment with ACV (5 lM); 4- treatment with GEV (0.13 lM).
Fig. 6. Effects of glucoevatromonoside (GEV), acyclovir (ACV), furosemide (FUR),
potassium chloride (KCl) and their combinations on HSV-1 (KOS strain) protein
expression; proteins were extracted and analyzed by Western Blotting. Columns:
1- cell control;2- virus control;3- treatmentwithACV (5 lM);4- treatmentwithGEV
(0.13 lM) + ACV (5 lM); 5- treatment with GEV (0.13 lM); 6- Virus control cultured
withmedium supplementedwith KCl; 7- treatmentwith GEV culturedwithmedium
supplemented with KCl; 8- treatment with FUR (500 lM); 9- treatment with GEV
(0.13 lM) + FUR (500 lM); 10- Cell control cultured with medium supplemented
with KCl.
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different concentrations of glucoevatromonoside and digitoxin
were calculated. These compounds inhibited HSV-1 release in a
concentration-dependent manner. However, the glucoevatro-
monoside at its IC50/2 (0.065 lM) was more effective (99.7% of vir-
al release inhibition) than the digitoxin at its IC50/2 (0.17 lM. (76%
of viral release inhibition).
It is well known that HSV infect epidermis and mucosae cells,
and a rapid viral cell-to-cell spread is very important to the estab-lishment of productive primary or recurrent infections in humans
(Nyberg et al., 2004). The effect of different concentrations
(0.015–0.25 lM) of glucoevatromonoside on HSV-1 cell-to-cell
spread was evaluated through a viral plaque size reduction assay,
and the results showed a signiﬁcant (p < 0.001) reduction in the
areas of formed viral plaques (from 56% to 98%), when compared
to those formed in viral control (data not shown). This effect could
be a consequence of the inhibition of viral release.
Table 1 demonstrate the highly antiherpetic activity against
acyclovir-resistant strain, and this fact suggests that the targets
of cardenolides are probably different from those of acyclovir. So,
the potential synergistic effects between glucoevatromonoside
and acyclovir were tested at different concentrations (Table 2).
The results shown CI values <1 indicating synergism between these
compounds. In the same way, Hartley et al. (2006) were able to
demonstrate synergism between digoxin and furosemide and
improvement of anti-adenovirus and anti-cytomegalovirus activ-
ity. These ﬁndings corroborate the potential antiherpetic activity
of glucoevatromonoside and support its use either alone or in com-
bination with acyclovir for the treatment of herpes infections.
Glucoevatromonoside is a natural cardiac glycoside, although
its capacity of Na+K+ATPase inhibition has not been reported yet.
Therefore, an anti-ATPase assay was performed to assess this po-
tential activity. Digoxigenin, digitoxin and digitoxin were used as
positive controls (Pullen et al., 2004), and digitoxose was used as
a negative control. All tested cardenolides inhibited the Na+K+ATP-
ase activity, and Table 3 shows the values of IC50.
The Na+K+ATPase inhibition would justify the inhibition of virus
release if the energy used by this process was obtained from this
system (Nagai et al., 1972). Hence, the inhibition of viral protein
synthesis caused by glucoevatromonoside could be explained by
the reduction of K+ concentration into the cells, which is a conse-
quence of the inhibition of this enzyme, since it is known that sev-
eral enzymes, including those related to viral protein synthesis,
Table 2
Synergistic effects of combination of glucoevatromonoside (GEV) with acyclovir (ACV) on anti-HSV activity.
Compounds combination ratio Sample concentration (lM) Mean percentage of inhibition (%) Experimental CI values Description (Graded symbols)
GEV ACV GEV + ACV
2  IC50 0.260 6.900 100.0 0.779 Moderate synergism (+ +)
1  IC50 0.130 3.450 92.2 0.710 Moderate synergism (+ +)
0.5  IC50 0.065 1.725 66.0 0.657 Synergism (+ + +)
CI: Combination Index, a quantitative measure calculated by Calcusyn Software. This index quantiﬁes the interaction between the tested compounds as described by Chou
(2006). The CI value from 0.10 to 0.30 means strong synergism, 0.30 to 0.70 means synergism, 0.70 to 0.85 means moderate synergism, and 0.85 to 0.90 means slight
synergism. The values represent the mean of two independent experiments.
Table 3
Inhibition of Na+K+ATPase by tested cardenolides.
Compound IC50 (lM)
Digitoxigenin 0.34 ± 0.03
Digitoxin 0.34 ± 0.01
Digoxigenin 1.04 ± 0.19
Gluevatromonoside 0.67 ± 0.16
Digitoxose NA
NA: no activity. IC50 = concentration that inhibited 50% of Na+K+ATPase activity. The
values represent the mean ± standard deviation of two independent experiments.
J.W. Bertol et al. / Antiviral Research 92 (2011) 73–80 79require K+ for its activation (Di Cera, 2006). Due to the depletion of
K+, it seems that the inhibition of viral macromolecules by this car-
denolide was not complete, because its antiviral activity was re-
versed when the K+ concentration was restored. Hence, we
believe that the antiviral activity of glucoevatromonoside could
be a consequence of its primary action on the cellular electrochem-
ical gradient causing no damage to the host cells (Hartley et al.,
1993), and leading to a secondary action, which is the inhibition
of viral replication. Accordingly, it acts discretely modifying the
distribution and concentration of K+ intracellular ion, and also
affecting the synthesis of essential co-factors in the viral
replication.
As it is well known, cardenolides have a long story of therapeu-
tic applications and are frequently associated to systemic toxicity,
but recent in vitro and in vivo toxicological results, and epidemio-
logical data support new roles for such drugs in the treatment of
several diseases, including cancer, neurological diseases and some
viral infections (Prassas and Diamandis, 2008).4. Conclusions
Taken together, the obtained results showed that glucoevatro-
monoside presents inhibitory effects of HSV-1 replication that
seems to occur by the inhibition of viral protein synthesis (ICP27,
UL42, gB and gD), the blockage of virus release, and the reduction
of viral cell-to-cell spread. This compound also showed anti-
Na+K+ATPase activity, suggesting that cellular electrochemical gra-
dient alterations might be involved in the mechanism of viral inhi-
bition. These results alongside with those previously obtained by
other authors suggest that this group of natural compounds might
be promising for future antiviral drug design.Acknowledgements
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